# EDGAR Filing Document

**Accession Number:** 0001113423
**File Stem:** 0001493152-26-022542
**Filing Date:** 2026-5
**Character Count:** 6656
**Document Hash:** 5699434895c229b77f2e5c26554d4aa6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-022542.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0001493152-26-022542

**CONFORMED SUBMISSION TYPE**: SC 13E3/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260512

**DATE AS OF CHANGE**: 20260512

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13E3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-51184
- **FILM NUMBER:** 26969943

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13E3/A

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Amendment No. 3 to** 

**SCHEDULE 13E-3**

**Rule 13e-3 Transaction Statement<br> (Pursuant to Section 13(e) of the Securities Exchange Act of 1934)**

**COSCIENS Biopharma Inc.**

(Name of the Issuer)

**COSCIENS Biopharma Inc.**<br> (Name of Persons Filing Statement)

**Common Stock, No Par Value per Share**

(Title of Class of Securities)

**22112H101**

(CUSIP Number of Class of Securities)

---

| | |
|:---|:---|
| **Peter Puccetti** |  |
| **Interim CEO and Chairman of the Board** |  |
| COSCIENS Biopharma Inc. | **Scott Saks** |
| **Telephone: (843) 900-3223** | **Norton Rose Fulbright US LLP** |
| **E-mail:** | **1301 Avenue of the Americas** |
| **c/o Borden Ladner Gervais, LLP,** | **New York, New York 10019-6022** |
| **22 Adelaide Street West, Suite 3400,** | **United States** |
| **Toronto ON M5H 4E3, Canada** | **(212) 318-3151** |

---

(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communication on<br> Behalf of Person(s) Filing Statement)

This statement is filed in connection with (check the appropriate box):

a. ☒ The
 filing of solicitation materials or an information statement Notice subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under
 the Securities Exchange Act of 1934.

b. ☐ The
 filing of a registration statement under the Securities Act of 1933.

c. ☐ A
 tender offer.

d. ☐ None
 of the above.

Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☒

Check the following box if the filing is a final amendment reporting the results of the transaction: ☐

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction, passed upon the merits or fairness of this transaction, or passed upon the adequacy or accuracy of the disclosure in this transaction statement on Schedule 13E-3. Any representation to the contrary is a criminal offense.**

**INTRODUCTION**

This Amendment No. 3 amends and supplements the Rule 13e-3 Transaction Statement on Schedule 13E-3 that was filed by COSCIENS Biopharma Inc. (referred to herein as "**Company**" or "**subject company**" or "**filing person**") with the Securities and Exchange Commission (the "**Commission**") on April 4, 2026, as amended by Amendment No. 1 filed on May 4, 2026, and Amendment No. 2 filed on May 8, 2026 (the "**Transaction Statement**").

This Amendment No. 3 to the Transaction Statement is being filed with the Commission to amend and restate Item 13 of the Schedule 13E-3.

Except as set forth in this Amendment No. 3 to the Transaction Statement, all information in the Transaction Statement remains unchanged.

**Item 13. Financial Information**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Financial information*. The audited financial statements of the Company for the two years ended
 December 31, 2024 and 2025 are incorporated herein by reference to the Company's Form
 20-F for the year ended December 31, 2025, originally filed on March 25, 2026 (see page F-1
 and the following pages). The condensed interim consolidated financial statements as of March
 31, 2026 and for the three-month periods ended March 31, 2026 and 2025, are incorporated by
 reference to Exhibit 99.1 to the current report on Form 6-K furnished by the Company to
 the Commission on May 12, 2026. The information set forth in the Circular in the section
 entitled "Share Capital Amendment – Financial Information" is incorporated
 herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Pro forma information*. The information set forth in the Circular in the section entitled
 "Share Capital Amendment – Financial Information – Pro Forma Information"
 is incorporated herein by reference.

**SIGNATURES**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Transaction Statement is true, complete, and correct.

---

| | |
|:---|:---|
| COSCIENS BIOPHARMA INC. | COSCIENS BIOPHARMA INC. |
| By: | */s/ Giuliano La Fratta* |
| Name: | Giuliano La Fratta |
| Title: | Chief Financial Officer |

---

Dated: May 12, 2026